Drugs / trifluridine/tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05201352 | Oct 2022 → Oct 2026 expected | colorectal cancer | Centre Georges Francois Leclerc | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trifluridine/tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05201352 ↗ |